NASDAQ · MIRA
Healthcare · Drug Manufacturers - General
$0.63
Down-$0.05 (-7.76%)
Updated Oct 23, 2026, 6:57 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MIRA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
MIRA closed at $0.63 after 21 trading sessions, down 25.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $0.7296 | $0.7296 | $0.6216 | $0.6289 | 100.25K |
| Oct 21, 2026 | $0.665 | $0.6927 | $0.665 | $0.6818 | 130.19K |
| Oct 20, 2026 | $0.645 | $0.6606 | $0.645 | $0.6501 | 10.46K |
| Oct 19, 2026 | $0.626 | $0.6474 | $0.6227 | $0.6421 | 66.06K |
| Oct 16, 2026 | $0.68 | $0.68 | $0.6309 | $0.6323 | 123.16K |
| Oct 15, 2026 | $0.6351 | $0.6791 | $0.626 | $0.6581 | 128.65K |
| Oct 14, 2026 | $0.6671 | $0.6857 | $0.66 | $0.6821 | 75.88K |
| Oct 13, 2026 | $0.6994 | $0.70 | $0.66 | $0.6664 | 67.89K |
| Oct 12, 2026 | $0.759 | $0.759 | $0.6847 | $0.7054 | 90.01K |
| Oct 9, 2026 | $0.72 | $0.7498 | $0.703 | $0.7455 | 52.43K |
| Oct 8, 2026 | $0.71 | $0.71 | $0.6805 | $0.703 | 142.66K |
| Oct 7, 2026 | $0.722 | $0.7409 | $0.703 | $0.71 | 67.73K |
| Oct 6, 2026 | $0.759 | $0.7601 | $0.70 | $0.7118 | 105.73K |
| Oct 5, 2026 | $0.7301 | $0.7501 | $0.7105 | $0.7355 | 89.42K |
| Oct 2, 2026 | $0.73 | $0.7581 | $0.7107 | $0.7301 | 158.39K |
| Oct 1, 2026 | $0.84 | $0.85 | $0.62 | $0.723 | 668.29K |
| Sep 30, 2026 | $0.859 | $0.8694 | $0.82 | $0.8448 | 72.09K |
| Sep 29, 2026 | $0.8703 | $0.90 | $0.8645 | $0.8715 | 63.23K |
| Sep 28, 2026 | $0.898 | $0.9112 | $0.8753 | $0.9033 | 65.82K |
| Sep 25, 2026 | $0.8602 | $0.90 | $0.85 | $0.90 | 95.12K |
| Sep 24, 2026 | $0.8577 | $0.86 | $0.8312 | $0.8395 | 54.09K |
The latest Smart Investors Daily articles mentioning MIRA.
Company
Market Activity
Research & News
MIRA research
Company profile and research snapshot.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | Maxim Group | Buy | — |
| Sep 30, 2024 | Rodman & Renshaw | Buy | — |
| Aug 5, 2024 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 3, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/1904286/000149315226008707/form8-k.htm
Benzinga · Feb 3, 2026
Phase 1 Progress and Phase 2a Development PlansThe ongoing randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetics of single and multiple oral
Benzinga · Feb 2, 2026
SEC Filing.
accessnewswire.com · Oct 24, 2025
Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire / October 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the initiation of the multiple ascending dose (MAD) portion of its ongoing Phase 1 clinical trial evaluating its lead oral candidate, Ketamir-2, in healthy volunteers. The Company also announced that it has selected chemotherapy-induced peripheral neuropathy (CIPN) - a common and debilitating side effect of cancer treatment - as the lead indication for its planned Phase 2a clinical evaluation.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MIRA.
